Burnie Academy
Amycretin: one molecule that hits GLP-1 and amylin

Amycretin: one molecule that hits GLP-1 and amylin

Amycretin is an experimental Novo Nordisk drug that targets both GLP-1 and amylin in one molecule. Early trials show strong weight loss, but it is not approved and not available yet.

13 Jul 2026 · Burnie Academy
amycretin amylin glp-1 weight-loss-medicines

Imagine one medicine that does two hunger-taming jobs at once. That is the idea behind amycretin. It is a new, experimental drug from Novo Nordisk. It is not approved anywhere, not sold in India, and still years away. But the early science is exciting, so let us look at it honestly.

CONTINUE READING FOR FREE

Unlock the complete article

Register with just your mobile number and OTP. No password and no payment.

Use this same phone number in the Burnie mobile app. Your profile, liked articles and favourites will stay synced.

By continuing, you agree to Burnie's Terms and Privacy Policy.

Track your food the honest way

Burnie helps you see your estimated calorie deficit with familiar Indian foods — no fake precision, no guilt trips.

Get Burnie on the App Store

Sign in with the same mobile number you use for Academy. Android public availability is being expanded.